B Group, Inc. — 13F Holdings & Portfolio

CIK 2043476 · latest 13F-HR filed 2026-08-14

B Group, Inc. manages $213.0M in 13F-reported U.S. long-equity assets across 19 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are QQQ (17.29%), ADMA (12.82%), PALI (11.20%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position and exited 3; 10 existing positions rose in reported value and 2 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

AUM

$213.0M

Long-equity book

Holdings

Distinct positions

Period

2026-06-30

Filed 2026-08-14

Q/Q Activity

+1 / −3 / ↑10 / ↓2

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

ADMA15.5% · +2%PALI13.5% · 0%NRXP9.5% · +36%FTH8.7% · new TSHA7.0% · 0%PRAX6.3% · 0%CLLS5.6% · 0%ZLAB4.9% · 0%GPCR4.3% · +10%ORKA4.1% · 0%IOVA3.5% · 0%SYRE3.5% · -30%AURA3.1% · +28%ASMB2.7% · 0%DRUG2.7% · 0%RARE2.6% · 0%SGHT2.1% · 0%FHTX0.6% · +96%

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

4 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 79.2%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Mar 3, 2026.

Address

2900 MCKINNON STREET
SUITE 1101
DALLAS, TX 75201

Phone

469-436-3669 EXT 501

Name	Title / Status	Ownership	Type
MUHL, BRANDEN, BOWEN Control	CHIEF EXECUTIVE OFFICER / SOLE MEMBER since Aug 2000	75% or more	Individual

Ownership & leadership changes · 1 filing with changes since Sep 28, 2020

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Apr 22, 2024 filing

No longer listedBERKELEY, WILLIAM, PEYTON · CHIEF INVESTMENT OFFICER · Less than 5% · control person · listed since Aug 2000

Sep 28, 2020 filing (earliest on record)

ListedBERKELEY, WILLIAM, PEYTON · CHIEF INVESTMENT OFFICER · Less than 5% · control person
ListedMUHL, BRANDEN, BOWEN · CHIEF EXECUTIVE OFFICER / SOLE MEMBER · 75% or more · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

Top Adds (vs prior quarter)

NRX PHARMACEUTICALS INC$10.3M +161.9%
TAYSHA GENE THERAPIES INC$4.2M +52.3%
PALISADE BIO INC$3.9M +19.4%
ORUKA THERAPEUTICS INC$3.5M +94.0%
ULTRAGENYX PHARMACEUTICAL IN$1.7M +59.4%

Show all 10 →

Top Trims

ADMA BIOLOGICS INC-$1.6M -5.5%
CELLECTIS S A-$557.9K -5.4%

New Positions

FAETH THERAPEUTICS INC$15.3M

Exited Positions

Loading…

#	Issuer	Symbol	CUSIP	Value	Δ

B Group, Inc. Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

#	Issuer	Symbol	CUSIP	Value	Weight	Shares	Type
1	INVESCO QQQ TR Put	QQQ	46090E953	$36.8M	17.29%	50,000	SH
2	ADMA BIOLOGICS INC	ADMA	000899104	$27.3M	12.82%	3,262,542	SH
3	PALISADE BIO INC	PALI	696389402	$23.9M	11.20%	11,414,285	SH
4	NRX PHARMACEUTICALS INC	NRXP	629444209	$16.7M	7.86%	4,091,767	SH
5	FAETH THERAPEUTICS INC	FTH	81728A207	$15.3M	7.16%	610,169	SH
6	TAYSHA GENE THERAPIES INC	TSHA	877619106	$12.3M	5.76%	1,800,556	SH
7	PRAXIS PRECISION MEDICINES I	PRAX	74006W207	$11.1M	5.22%	33,237	SH
8	CELLECTIS S A	CLLS	15117K103	$9.8M	4.62%	3,281,501	SH
9	ZAI LAB LTD	ZLAB	98887Q104	$8.6M	4.02%	450,646	SH
10	STRUCTURE THERAPEUTICS INC	GPCR	86366E106	$7.5M	3.53%	140,000	SH
11	ORUKA THERAPEUTICS INC	ORKA	687604108	$7.1M	3.35%	75,000	SH
12	IOVANCE BIOTHERAPEUTICS INC	IOVA	462260100	$6.2M	2.93%	1,500,000	SH
13	SPYRE THERAPEUTICS INC	SYRE	00773J202	$6.2M	2.92%	70,000	SH
14	AURA BIOSCIENCES INC	AURA	05153U107	$5.4M	2.55%	764,243	SH
15	ASSEMBLY BIOSCIENCES INC	ASMB	045396207	$4.8M	2.27%	175,706	SH
16	BRIGHT MINDS BIOSCIENCES INC	DRUG	10919W405	$4.7M	2.22%	67,500	SH
17	ULTRAGENYX PHARMACEUTICAL IN	RARE	90400D108	$4.5M	2.12%	135,000	SH
18	SIGHT SCIENCES INC	SGHT	82657M105	$3.7M	1.72%	970,000	SH
19	FOGHORN THERAPEUTICS INC	FHTX	344174107	$976.0K	0.46%	200,000	SH

Filing History

Period	Filed	AUM	Holdings	Accession
2026-06-30	2026-08-14	$213.0M	19	0001420506-26-001657
2026-03-31	2026-05-15	$134.9M	20	0001420506-26-001023
2025-12-31	2026-02-17	$135.4M	16	0001420506-26-000462
2025-09-30	2025-11-14	$135.9M	20	0001420506-25-003231

Filer Information

Address

2900 MCKINNON STREET
SUITE 1101
DALLAS, TX 75201

Phone

469-436-3669 EXT 501

Filing Manager

B Group, Inc.

DALLAS, TX

Signatory

David Chang

Chief Compliance Officer